Skip to Content

TIXYLIX DRY COUGH

Active substance(s): PHOLCODINE

View full screen / Print PDF » Download PDF ⇩
Transcript
SUMMARY OF PRODUCT CHARACTERISTICS

1

NAME OF THE MEDICINAL PRODUCT
Tixylix Dry Cough

2.

QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 5 ml contains Pholcodine 4 mg
For excipients, see 6.1.

3.
PHARMACEUTICAL FORM
Linctus
The product is a clear, colourless syrup with a sweet blackcurrant odour and taste.

4

CLINICAL PARTICULARS

4.1

Therapeutic indications
Cough Suppressant for relief of acute non-productive cough associated with
upper respiratory tract infection.
Route of administration: Oral

4.2

Posology and method of administration
The following doses are to be given 6 hourly as required. Do not exceed 4 doses in 24
hours.
Tixylix Dry Cough is contra-indicated in children under the age of 6 years.
6 - 10 years :

5 ml to 10 ml

Children of 6 -10 years of age: not to be used for more than 5 days without the advice
of a doctor. Parent or carers should seek medical attention if the child’s condition
deteriorates during treatment.
Do not exceed the stated dose
Keep out of the sight and reach of children

4.3.

Contra-indications

Hypersensitivity to pholcodine or to any of the excipients.
Not to be used in children under the age of 6 years.
Pholcodine should not be given to specific patients where suppression of the cough reflex is
inadvisable.
Pholcodine should not be given to subjects in, or at risk of developing respiratory failure.
Patients with chronic bronchitis, COPD, bronchiolitis or bronchiectasis due to sputum
retention.
Patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping such
treatment (see also section 4.5).

4.4.

Special Warnings and Precautions for Use

1. Should be used with caution by patients with liver or renal disease.
2. Ask a doctor before use if you suffer from a chronic or persistent cough, if you
have asthma, or are suffering from an acute asthma attack or where cough is
accompanied by excessive secretions.
3. Do not take with any other cough and cold medicine.
4. Use of pholcodine with alcohol or other CNS depressants may increase the
effects on the CNS and cause toxicity in relatively smaller doses.

Appearing on the Label or in the Leaflet (should one be provided)
If symptoms persist for more than 5 days consult your doctor.
If your child is taking other medicines consult your doctor or pharmacist.
Warning : Do not exceed the stated dose (in a rectangle).
Keep all medicines out of the reach and sight of children.
Do not exceed the stated dose.
Do not take with any other cough and cold medicine.

4.5

Interaction with other medicinal products and other forms of interaction
Not to be used in patients taking MAOIs or within 14 days of stopping treatment.
Interaction with neuromuscular blocking agents (anaphylaxis) has been reported.

The reduction of blood pressure caused by antihypertensives may accentuate the
hypotensive effects of pholcodine. Diuretics may have the same effect.
Pholcodine may enhance the sedative effect of central nervous system depressants
including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives and
tranquillisers (phenothiazines and tricyclic antidepressants).

4.6

Pregnancy and lactation
Not applicable.

4.7

Effects on ability to drive and use machines
Not applicable.

4.8

Undesirable effects
The following side effects may be associated with the use of pholcodine:
Occasional drowsiness, dizziness, excitation, confusion, sputum retention, vomiting,
gastrointestinal disturbances (nausea and constipation) and skin reactions including
rash.
Immune system disorders have been noted including hypersensitivity reactions and
anaphylaxis.

4.9

Overdose
Restlessness, ataxia and excitement may occur. Treatment should be directed to
elimination of ingested material by gastric lavage. General supportive measures
should be followed. There may be respiratory depression and pin-point pupils :
Naloxone 0.01 - 0.1 mg/kg should reverse this. If initial response is not maintained
this dose may be repeated.
It is thought to be of low toxicity, but the effects in overdosage will be potentiated by
simultaneous ingestion of alcohol and psychotropic drugs.
Symptoms: These include nausea, drowsiness, restlessness, excitement, ataxia and
respiratory depression.
Management: Treatment of overdose should be symptomatic and supportive. Gastric
lavage may be of use. Naloxone has been used successfully to reverse central or
peripheral opioid effects in children (0.01mg/kg body weight). Other treatment option

is activated charcoal (1g/kg body weight) if more than 4mg/kg has been ingested
within 1 hour, provided the airway can be protected.

5.

PHARMACOLOGICAL PROPERTIES

5.1

Pharmacodynamic properties
Pholcodine is a cough suppressant with little analgesic and sedative action. Its
effects on depression of respiration are less than those of morphine.

5.2

Pharmacokinetic properties
The duration of action is 4 - 5 hours.
Biotransformation to morphine is not apparent.

5.3

Preclinical safety data
None.

6.

PHARMACEUTICAL PARTICULARS

6.1

List of excipients
Liquid maltitol
Glycerol
Hydroxyethylcellulose
Citric acid
Sodium benzoate
Acesulfame potassium
Blackcurrant flavour (containing propylene glycol)
Vanilla flavour (containing propylene glycol)
Purified water

6.2

Incompatibilities
Not applicable.

6.3

Shelf life
24 months.

6.4

Special precautions for storage
None.

6.5

Nature and contents of container
Amber glass bottle with wadded aluminium ROPP closure,
or wadded, polypropylene or polypropylene/HDPE, child resistant tamper
evident closure.
Pack sizes: 100 ml, 1000 ml.

6.6

Instruction for use/handling
None.

7.

MARKETING AUTHORISATION HOLDER
Novartis Consumer Health UK Limited
Wimblehurst Road
Horsham
West Sussex
RH12 5AB
United Kingdom
Trading as Novartis Consumer Health

8.

MARKETING AUTHORISATION NUMBER
PL 00030/0090

9

DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
25/10/2004

10

DATE OF REVISION OF THE TEXT
03/06/2009

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide